Related Experiment Videos
Orlistat inhibits dietary cholesterol absorption
B Mittendorfer1, R E Ostlund, B W Patterson
1Department of Internal Medicine and Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Obesity Research
|October 12, 2001
Summary
Orlistat medication significantly reduces dietary cholesterol absorption in obese individuals. This mechanism may independently improve cholesterol levels and lipoprotein metabolism beyond weight loss effects.
Area of Science:
- Metabolic research
- Pharmacology
- Obesity studies
Background:
- Orlistat inhibits intestinal lipases, reducing dietary triglyceride absorption.
- Orlistat therapy is linked to greater reductions in low-density lipoprotein-cholesterol (LDL-C) than expected from weight loss alone.
Purpose of the Study:
- To investigate the effect of orlistat on dietary cholesterol absorption.
- To determine if reduced cholesterol absorption is a mechanism for orlistat's independent effect on plasma cholesterol concentration.
Main Methods:
- A standardized meal with dual cholesterol tracers (oral and intravenous) was used to measure cholesterol absorption.
- Eighteen subjects with class II abdominal obesity participated in a crossover study assessing orlistat's effect on cholesterol absorption.
Main Results:
- Orlistat treatment resulted in a 25% reduction in dietary cholesterol absorption (from 59% to 44%, p < 0.01).
- The tracer method for determining cholesterol absorption demonstrated good reproducibility.
Conclusions:
- Orlistat effectively inhibits dietary cholesterol absorption in obese subjects.
- This inhibition may contribute to beneficial effects on lipoprotein metabolism independent of weight reduction.